Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 28, Issue 25, Pages 4006-4012Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2009.27.5388
Keywords
-
Categories
Funding
- Merck
Ask authors/readers for more resources
There is increasing evidence that many cancers, including breast cancer, contain populations of cells that display stem-cell properties. These breast cancer stem cells, by virtue of their relative resistance to radiation and cytotoxic chemotherapy, may contribute to treatment resistance and relapse. The elucidation of pathways that regulate these cells has led to the identification of potential therapeutic targets. A number of agents capable of targeting breast cancer stem cells in preclinical models are currently entering clinical trials. Assessment of the efficacy of the agents will require development of innovative clinical trial designs with appropriate biologic and clinical end points. The effective targeting of breast cancer stem cells has the potential to significantly improve outcome for women with both early-stage and advanced breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available